Adjuvant Activity of CpG Oligodeoxynucleotides

REFERENCES

• P. Marrack and J. Kappler, Subversion of the immune system by pathogens, Cell, 76: 323–332, 1994. [CSA]
   PubMed Web of Science ®Google Scholar
• R. Medzhitov and C.A. Janeway, Innate immunity: impact on the adaptive immune response, Cur. Opin. Immunol., 9: 4–9, 1997. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R. Medzhitov and C.A. Janeway, Innate immunity: the virtues of a nonclonal system of recognition, Cell, 91: 295–298, 1998. [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• W.E. Paul (ed.), Fundamental immunology. New York: Raven Press, 1993.
   Google Scholar
• D.M. Underhill and A. Ozinsky, Toll-like receptors: Key mediators of microbe detection, Curr. Opin. Immunol., 14: 103–110, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• T. Vasselon and P.A. Detmers, Toll receptors: a central element in innate immune responses, Infect. Immun., 70: 1033–1041, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A. Razin and J. Friedman, DNA methylation and its possible biological roles, Prog. Nucleic Acid Res. Mol Biol., 25: 33–52, 1981. [CSA]
   PubMedGoogle Scholar
• L.R. Cardon, C. Burge, D.A. Clayton, and S. Karlin, Pervasive CpG suppression in animal mitochondrial genomes, Proc. Natl. Acad. Sci. U.S.A., 91: 3799–3803 1994. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H. Hemmi, O. Takeuchi, T. Kawai, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira, A Toll-like receptor recognizes bacterial DNA, Nature, 408: 740–745, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• F. Takeshita, C.A. Leifer, I. Gursel, K. Ishii, S. Takeshita, M. Gursel, and D.M. Klinman, Cutting Edge: role of toll-like receptor 9 in CpG DNA-induced activation of human cells, J. Immunol., 167: 3555–3558, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• S. Bauer, C.J. Kirschning, H. Hacker, V. Redecke, S. Hausmann, S. Akira, H. Wagner, and G.B. Lipford, Human TLR9 confers responsiveness to bacterial DNA via species -specific CpG motif recognition, Proc. Natl. Acad. Sci. U.S.A., 98: 9237–9242, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.M. Krieg, A. Yi, S. Matson, T.J. Waldschmidt, G.A. Bishop, R. Teasdale, G.A. Koretzky, and D.M. Klinman, CpG motifs in bacterial DNA trigger direct B-cell activation, Nature, 374: 546–548, 1995. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S. Yamamoto, T. Katoaka, O. Yano, E. Kuramoto, S. Shimada, and T. Tokunaga, Antitumor effect of nucleic acid fraction from bacteria, Proc. Jpn. Soc. Immunol., 48: 272–281, 1989. [CSA]
   Google Scholar
• S. Yamamoto, T. Yamamoto, T. Katoaka, E. Kuramoto, O. Yano, and T. Tokunaga, Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity, J. Immunol., 148: 4072–4076, 1992. [CSA]
   PubMed Web of Science ®Google Scholar
• D.M. Klinman, A. Yi, S.L. Beaucage, J. Conover, and A.M. Krieg, CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFNg, Proc. Natl. Acad. Sci. U.S.A., 93: 2879–2883, 1996. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• K.J. Ishii, F. Takeshita, I. Gursel, M. Gursel, J. Conover, A. Nussenzweig, and D.M. Klinman, Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation, J. Exp. Med., 196: 269–274, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M. Gursel, D. Verthelyi, I. Gursel, K.J. Ishii, and D.M. Klinman, Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotides, J. Leukoc. Biol., 71: 813–820, 2002. [CSA]
   PubMed Web of Science ®Google Scholar
• V. Hornung, S. Rothenfusser, S. Britsch, A. Krug, B. Jahrsdorfer, T. Giese, S. Endres, and G. Hartmann, Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides, J. Immunol., 168: 4531–4537, 2002. [CSA]
   PubMed Web of Science ®Google Scholar
• S. Sun, X. Zhang, D.F. Tough, and J. Sprent, Type I interferon-mediated stimulation of T cells by CpG DNA, J. Exp. Med., 188: 2335–2342, 1998. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• K.J. Stacey, M.J. Sweet, and D.A. Hume, Macrophages ingest and are activated by bacterial DNA, J. Immunol., 157: 2116–2120, 1996. [CSA]
   PubMed Web of Science ®Google Scholar
• Z.D. Ballas, W.L. Rasmussen, and A.M. Krieg, Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA, J. Immunol., 157: 1840–1847, 1996. [CSA]
   PubMed Web of Science ®Google Scholar
• M.D. Halpern, R.J. Kurlander, and D.S. Pisetsky, Bacterial DNA induces murine interferon-gamma production by stimulation of IL-12 and tumor necrosis factor-alpha, Cell. Immunol., 167: 72–78, 1996. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R. Rankin, R. Pontarollo, X. Ioannou, A.M. Krieg, R. Hecker, L.A. Babiuk, and van Drunen Littel-van den Hurk, CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved, Antisense Nucleic. Acid. Drug. Dev., 11: 333–340, 2001. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• M. Roman, E. Martin-Orozco, J.S. Goodman, M. Nguyen, Y. Sato, A. Ronaghy, R.S. Kornbluth, D.D. Richman, D.A. Carson, and E. Raz, Immunostimulatory DNA sequences function as T helper-1 promoting adjuvants, Nat. Med., 3: 849–854, 1997. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D.H. Broide, G. Stachnick, D. Castaneda, J. Nayar, M. Miller, J.Y. Cho, M. Roman, J. Zubeldia, T. Hayashi, E. Raz, and T. Hyashi, Systemic administration of immunostimulatory DNA sequences mediates reversible inhibition of Th2 responses in a mouse model of asthma, J. Clin. Immunol., 21: 175–182, 2001. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• D. Verthelyi, K.J. Ishii, M. Gursel, F. Takeshita, and D.M. Klinman, Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs, J. Immunol., 166: 2372–2377, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• A. Krug, S. Rothenfusser, V. Hornung, B. Jahrsdorfer, S. Blackwell, Z.K. Ballas, S. Endres, A.M. Krieg, and G. Hartmann, Identification of CpG oligonucleotide sequences with high induction of IFNa/b in plasmacytoid dendritic cells, Eur. J. Immunol., 31: 2154–2163, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• N. Kadowaki, S. Ho, S. Antonenko, R.W. Malefyt, R.A. Kastelein, F. Bazan, and Y.J. Liu, Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens, J. Exp. Med., 194: 863–869, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A. Krug, A. Towarowski, S. Britsch, S. Rothenfusser, V. Hornung, R. Bals, T. Giese, H. Engelmann, S. Endres, A.M. Krieg, and G. Hartmann, Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12, Eur. J. Immunol., 31: 3026–3037, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M. Bauer, V. Redecke, J.W. Ellwart, B. Sherer, J.P. Kremer, H. Wagner, and G.B. Lipford, Bacterial CpG DNA triggers activation and maturation of human CD11c(−), CD123(+) dendritic cells, J. Immunol., 166: 5000–5007, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• G. Hartmann, J. Battiany, H. Poeck, M. Wagner, M. Kerkmann, N. Lubenow, S. Rothenfusser, and S. Endres, Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells, Eur. J Immunol., 33: 1633–1641, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J.D. Marshall, K. Fearon, C. Abbate, S. Subramanian, P. Yee, J. Gregorio, R.L. Coffman, and G. Van Nest, Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions, J. leukoc. Biol., 73: 781–792, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• G. Hartmann and A.M. Krieg, Mechanism and function of a newly identified CpG DNA motif in human primary B cells, J. Immunol., 164: 944–952, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• G. Hartmann, R.D. Weeratna, Z.K. Ballas, P. Payette, S. Blackwell, I. Suparto, W.L. Rasmussen, M. Waldshmidt, D. Sajuthi, R.H. Purcell, H.L. Davis, and A.M. Krieg, Delineation of a CpG phosphorothioate oligodeoxinucleotide for activating primate immune responses in vitro and in vivo, J. Immunol., 164: 1617–1624, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• D. Verthelyi, R.T. Kenney, R.A. Seder, A.A. Gam, B. Friedag, and D.M. Klinman, CpG oligodeoxynucleotides as vaccine adjuvants in primates, J. Immunol., 168: 1659–1663, 2002. [CSA]
   PubMed Web of Science ®Google Scholar
• t.S. Kanellos, I.D. Sylvester, V.L. Butler, A.G. Ambali, C.D. Partidos, A.S. Hamblin, and P.H. Russell, Mammalian granulocyte-macrophage colony stimulating factor and some CpG motifs have an effect on the immunogenicity of DNA and subunit vaccines in fish, Immunology, 96: 507–510, 1999. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H.L. Davis, I.I. Suparto, R.R. Weeratna, Jumintarto, D.D. Iskandriati, S.S. Chamzah, A.A. Ma'ruf, D.D. Nente, A.M. Krieg, Heriyanto, W. Smits, and D.D. Sajuthi, CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans, Vaccine, 18: 1920–1924, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D. Verthelyi and D.M. Klinman, Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates, Clin. Immunol., 109: 64–71, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D. Tang, M. DeVit, and S.A. Johnston, Genetic immunization is a simple method for eliciting an immune response, Nature, 356: 152–154, 1992. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J.B. Ulmer, J.J. Donnelly, S.E. Parker, G.H. Rhodes, P.L. Felgner, V.J. Dwarki, S.H. Gromkoski, R.R. Deck, C.M. DeWitt, and A. Friedman, Heterologous protection against influenza by injection of DNA encoding a viral protein [see comments] Science, 259: 1745–1749, 1993. [CSA]
   PubMed Web of Science ®Google Scholar
• M. Sedegah, R. Hedstrom, P. Hobart, and S.L. Hoffman, Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein, Proc. Natl. Acad. Sci. U.S.A., 91: 9866–9870, 1994. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• G. Mor, D.M. Klinman, S. Shapiro, E. Hagiwara, M. Sedegah, J.A. Norman, S.L. Hoffman, and A.D. Steinberg, Complexity of the cytokine and antibody response elicited by immunizing mice with Plasmodium yoelii circumsporozoite protein plasmid DNA, J. Immunol., 155: 2039–2046, 1995. [CSA]
   PubMed Web of Science ®Google Scholar
• R. Wang, D.L. Doolan, T.P. Le, R.C. Hedstrom, K.M. Coonan, Y. Charoenvit, and S.L. Hoffman, Induction of antigen specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine, Science, 282: 476–480, 1998. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S. Calarota, G. Bratt, S. Nordlund, J. Hinkula, A.D. Leandersson, E. Sandstrom, and B. Wahren, Cellular cytotoxic response induced by DNA vaccination in HIV-1 infected patients, Lancet, 351: 1320–1325, 1998. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• T. Jakob, P.S. Walker, A.M. Krieg, M.C. Udey, and J.C. Vogel, Activation of cutaneous dendritic cells by CpG containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA, J. Immunol., 161: 3042–3049, 1998. [CSA]
   PubMed Web of Science ®Google Scholar
• T. Sparwasser, E. Koch, R.M. Vabulas, K. Heeg, G.B. Lipford, J.W. Ellwart, and H. Wager, Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells, Eur. J. Immunol., 28: 2045–2054, 1998. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Y. Sato, M. Roman, H. Tighe, D. Lee, M. Corr, M. Nguyen, D.A. Carson, and E. Raz, Immunostimulatory DNA sequences necessary for effective intradermal gene immunization, Science, 273: 352–354, 1996. [CSA]
   PubMed Web of Science ®Google Scholar
• Y. Kojima, K.Q. Xin, T. Ooki, K. Hamajima, T. Oikawa, K. Shinoda, T. Ozaki, Y. Hoshino, N. Jounai, M. Nakazawa, D. Klinman, and K. Okuda, Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine, Vaccine, 20: 2857–2865, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• E.G. Rodriguez, D.M. Vazquez, A.M. Herrera, and C.A. Duarte, Enhanced cell-mediated IFN-gamma-secreting activity against the HIV-1IIIB V3 peptide of the TAB9 multiepitope after DNA vaccine backbone engineering, Biochem. Biophys. Res. Commun., 308: 713–718, 2003. [CSA], [CROSSREF]
   Google Scholar
• D.M. Klinman, G. Yamshchikov, and Y. Ishigatsubo, Contribution of CpG motifs to the immunogenicity of DNA vaccines, J. Immunol., 158: 3635–3642, 1997. [CSA]
   PubMed Web of Science ®Google Scholar
• A.M. Krieg, T. Wu, R. Weeratna, S.M. Efler, L. Love, L. Yang, A. Yi, D. Short, and H.L. Davis, Sequence motifs in adenoviral DNA block immune activation by stimuatory CpG motifs, Proc. Natl. Acad. Sci. U.S.A., 95: 12631–12636, 1998. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R. Weeratna, C.L. Brazolot, B. Millan, A.M. Krieg, and H.L. Davis, Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides, Antisense Nucleic. Acid. Drug Dev., 8: 351–356, 1998. [CSA]
   PubMedGoogle Scholar
• B. spies, H. Hochrein, M. Vabulas, K. Huster, D.H. Busch, F. Schmitz, A. Heit, and H. Wagner, Vaccination with plasmid DNA activates dendritic cells via TLR9 but functions in TLR9-deficient mice, J. Immunol., (in press), 2003. [CSA]
   Google Scholar
• D.M. Klinman, Therapeutic applications of CpG-containing oligodeoxynucleotides, Antisense Nucleic Acid Drug Dev., 8: 181–184, 1998. [CSA]
   PubMedGoogle Scholar
• D.M. Klinman, K.M. Barnhart, and J. Conover, CpG motifs as immune adjuvants, Vaccine, 17: 19–25, 1999. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• I. Gursel, M. Gursel, K.J. Ishii, and D.M. Klinman, Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides, J. Immunol., 167: 3324–3328, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• H.L. Davis, R. Weeranta, T.J. Waldschmidt, L. Tygrett, J. Schorr, and A.M. Krieg, CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen, J. Immunol., 160: 870–876, 1998. [CSA]
   PubMed Web of Science ®Google Scholar
• H. Shirota, K. Sano, N. Hirasawa, T. Terui, K. Ohuchi, T. Hattori, K. Shirato, and G. Tamura, Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells, J. Immunol., 167: 66–74, 2001. [CSA]
   PubMed Web of Science ®Google Scholar
• Z. Moldoveanu, L. Love-Homan, W.Q. Huang, and A.M. Krieg, CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus, Vaccine, 16: 1216–1224, 1998. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J. Kovarik, P. Bozzotti, L. Love-Homan, M. Pihlgren, H.L. Davis, P.-H. Lambert, A.M. Krieg, and C.A. Siegrist, CpG oligonucleotides can cirmcuvent the TH2 polorization of neonatal responses to vaccines but fail to fully redirect TH2 responses established by neonatal priming, J. Immunol., 162: 1611–1617, 1999. [CSA]
   PubMed Web of Science ®Google Scholar
• M.J. McCluskie and H.L. Davis, CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice, J. Immunol., 161: 4463–4466, 1998. [CSA]
   PubMed Web of Science ®Google Scholar
• C.L. Brazolot Millan, R. Weeratna, A.M. Krieg, C.A. Siegrist, and H.L. Davis, CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice, Proc. Natl. Acad. Sci. U.S.A., 95: 15553–15558, 1998. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J.W. Eastcott, C.J. Holmberg, F.E. Dewhirst, T.R. Esch, D.J. Smith, and M.A. Taubman, Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid, Vaccine, 19: 1636–1642, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R.F. Branda, A.L. Moore, A.R. Lafayette, L. Mathews, R. Hong, G. Zon, T. Brown, and J.J. McCormack, Amplification of antibody production by phosphorothioate oligodeoxynucleotides, J. Lab. Clin. Med., 128: 329–338, 1996. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.A. Horner, A. Ronaghy, P.M. Cheng, M.D. Nguyen, H.J. Cho, D. Broide, and E. Raz, Immunostimulatory DNA is a potent mucosal adjuvant, Cell Immunol., 190: 77–82, 1998. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M.J. McCluskie and H.L. Davis, Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants, Vaccine, 19: 413–422, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• H.M. Hernandez, M. Figueredo, N. Garrido, L. Sanchez, and J. Sarracent, Intranasal immunisation with a 62 kDa proteinase combined with cholera toxin or CpG adjuvant protects against Trichomonas vaginalis genital tract infections in mice, Int. J. Parasitol., 35: 1333–1337, 2005. [CSA], [CROSSREF]
   Google Scholar
• J. Sterzl and A.M. Silverstein, Developmental aspects of immunity, Adv. Immunol., 6: 337–459, 1967. [CSA]
   PubMedGoogle Scholar
• D.W. Hunt, H.I. Huppertz, H.J. Jiang, and R.E. Petty, Studies of human cord blood dendritic cells: Evidence for functional immaturity, Blood, 84: 4333–4343, 1994. [CSA]
   PubMed Web of Science ®Google Scholar
• R.A. Miller, The cell bilogy of aging: immunologic models, J. Gerontol., 44: B4, 1989. [CSA]
   PubMedGoogle Scholar
• M.L. Thoman and W.O. Weigle, The cellular and subcellular bases of immunosenescence, Adv. Immunol., 46: 221–261, 1989. [CSA]
   PubMed Web of Science ®Google Scholar
• W. Qin, J. Jiang, Q. Chen, N. Yang, Y. Wang, X. Wei, and R. Ou, CpG ODN enhances immunization effects of hepatitis B vaccine in aged mice, Cell Mol. Immunol., 1: 148–152, 2004. [CSA]
   PubMedGoogle Scholar
• C.A. Siegrist, M. Pihlgren, C. Tougne, S.M. Efler, M.L. Morris, M.J. AlAdhami, D.W. Cameron, C.L. Cooper, J. Heathcote, H.L. Davis, and P.H. Lambert, Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response, Vaccine, 23: 615–622, 2004. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• E.P. Diamant, C. Schechter, D.S. Hodes, and V.B. Peters, Immunogenicity of hepatitis B vaccine in human immunodeficiency virus-infected children, Pediatr. Infect. Dis. J., 12: 877–878, 1993. [CSA]
   PubMed Web of Science ®Google Scholar
• E.K. Wong, N.J. Bodsworth, M.A. Slade, B.P. Mulhall, and B. Donovan, Response to hepatitis B vaccination in a primary care setting: Influence of HIV infection, CD4 + lymphocyte count and vaccination schedule, Int. J STD AIDS, 7: 490–494, 1996. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• J. Pacanowski, S. Kahi, M. Baillet, P. Lebon, C. Deveau, C. Goujard, L. Meyer, E. Oksenhendler, M. Sinet, and A. Hosmalin, Reduced blood CD123 + (lymphoid) and CD11c + (myeloid) dendritic cell numbers in primary HIV-1 infection, Blood, 98: 3016–3021, 2001. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D. Verthelyi, M. Gursel, R.T. Kenney, J.D. Lifson, S. Liu, J. Mican, and D.M. Klinman, CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection, J. Immunol., 170: 4717–4723, 2003. [CSA]
   PubMed Web of Science ®Google Scholar
• T.R. Jones, N. Obaldia, R.A. Gramzinski, Y. Charoenvit, N. Kolodny, S. Kitov, H.L. Davis, A.M. Krieg, and S.L. Hoffman, Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenic vaccine in Aotus monkeys, Vaccine, 17: 3065–3071, 1999. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• X.H.L.S.C.D.I.B. Klinman DM, CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques, Vaccine, 171: 5908–5912, 2003. [CSA]
   Google Scholar
• E. von Stebut, Y. Belkaid, B.V. Nguyen, M. Cushing, D.L. Sacks, and M.C. Udey, Leishmania major infected murine langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous leishmaniasis, Eur. J. Immunol., 30: 3498–3506, 2000. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S.A. Halperin, G. Van Nest, B. Smith, S. Abtahi, H. Whiley, and J.J. Eiden, A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant, Vaccine, 21: 2461–2467, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D.M. Klinman, K.J. Ishii, M. Gursel, I. Gursel, S. Takeshita, and F. Takeshita, Immunotherapeutic applications of CpG-containing oligodeoxynucleotides, Drug. News Perspect., 13: 289–296, 2000. [CSA]
   Google Scholar
• D.M. Klinman, CpG DNA as a vaccine adjuvant, Expert. Rev. Vaccines., 2: 305–315, 2003. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• D. Rynkiewicz, M. Rathkopf, J. Ransom, I. Sim, L. Giri, J. Quinn, T. Waytes, M. Al-Adhami, W. Johnson, and C. Nielsen, Marked enhancement of antibody response to anthrax vaccine adsorbed with CpG 7909 in healthy volunteers. ICAAC abstract LB-25, 2005.
   Google Scholar
• G.S. Gilkeson, P. Riuz, D. Howell, J.B. Lefkowith, and D.S. Pisetsky, Induction of immune-mediated glomerulonephritis in normal mice immunized with bacterial DNA, Clin. Immunol. Immunopathol., 68: 283–292, 1993. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• G.S. Gilkeson, A.M. Pippen, and D.S. Pisetsky, Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA, J. Clin. Invest., 95: 1398–1402, 1995. [CSA]
   PubMed Web of Science ®Google Scholar
• A.D. Steinberg, A.M. Krieg, M.F. Gourley, and D.M. Klinman, Theoretical and experimental approaches to generalized autoimmunity, Immunol. Rev., 118: 129–163, 1990. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• D.M. Klinman, Polyclonal B cell activation in lupus-prone mice precedes and predicts the development of autoimmune disease, J. Clin. Invest., 86: 1249–1254, 1990. [CSA]
   PubMedGoogle Scholar
• M. Linker-Israeli, R. Deans, D. Wallace, J. Prehn, T. Ozeri-Chen, and J. Klinenberg, Elevated levels of endogenous IL-6 in systemic lupus erythematosus, J. Immunol., 147: 117–123, 1991. [CSA]
   PubMed Web of Science ®Google Scholar
• A.M. Krieg, CpG DNA: A pathogenic factor in systemic lupus erythematosus? J. Clin. Immunol., 15: 284–292, 1995. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A.-K. Yi, P. Hornbeck, D.E. Lafrenz, and A.M. Krieg, CpG DNA rescue of murine B lymphoma cells from anti-IgM induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xl, J. Immunol., 157: 4918–4925, 1996. [CSA]
   PubMed Web of Science ®Google Scholar
• G. Mor, M. Singla, A.D. Steinberg, S.L. Hoffman, K. Okuda, and D.M. Klinman, Do DNA vaccines induce autoimmune disease? Hum. Gene. Ther., 8: 293–300, 1997. [CSA]
   PubMed Web of Science ®Google Scholar
• A. Katsumi, N. Emi, A. Abe, Y. Hasegawa, M. Ito, and H. Saito, Humoral and cellural immunity to an encoded protein induced by direct DNA injection, Hum. Gene. Ther., 5: 1335–1339, 1994. [CSA]
   PubMed Web of Science ®Google Scholar
• G.S. Gilkeson, J.S. Conover, M. Halpern, D.S. Pisetsky, A. Feagin, and D.M. Klinman, Effects of bacterial DNA on cytokine production by (NZB/NZW)F1 mice, J. Immunol., 161: 3890–3895, 1998. [CSA]
   PubMed Web of Science ®Google Scholar
• B.M. Segal, D.M. Klinman, and E.M. Shevach, Microbial products induce autoimmune disease by an IL-12 dependent process, J. Immunol., 158: 5087–5091, 1997. [CSA]
   PubMed Web of Science ®Google Scholar
• B.M. Segal, J.T. Chang, and E.M. Shevach, CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalotogenic T cells in vivo, J. Immunol., 164: 5683–5688, 2000. [CSA]
   PubMed Web of Science ®Google Scholar
• K. Bachmaier, N. Meu, L.M. Maza, S. Pal, A. Nessel, and J.M. Penninger, Chlamydia infections and heart disease linked through antigenic mimicry, Science, 283: 1335–1339, 1999. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• R.A. Zeuner, D. Verthelyi, M. Gursel, K.J. Ishii, and D.M. Klinman, Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis, Arthritis Rheum., 48: 1701–1707, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• T. Sparwasser, T. Meithke, G. Lipford, K. Borschert, H. Hicker, K. Heeg, and H. Wagner, Bacterial DNA causes septic shock, Nature, 386: 336–338, 1997. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• J.S. Cowdery, J.H. Chace, A.-K. Yi, and A.M. Krieg, Bacterial DNA induces NK cells to produce IFNgamma in vivo and increases the toxicity of lipopolysaccharides, J. Immunol., 156: 4570–4575, 1996. [CSA]
   PubMed Web of Science ®Google Scholar
• G. Hartmann, A. Krug, K. Waller, and S. Endres, Oligodeoxynucleotides enhance LPS-stimulated synthesis of TNF: dependence on phosphorothioate modification and reversal by heparin, Mol. Med., 2: 429–438, 1996. [CSA]
   PubMed Web of Science ®Google Scholar
• D.M. Klinman, M. Takeno, M. Ichino, M. Gu, G. Yamshchikov, G. Mor, and J. Conover, DNA vaccines: Safety and efficacy issues, Springer Semin Immunopathol, 19: 245–256, 1997. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• B.R. Yacyshyn, C. Barish, J. Goff, D. Dalke, M. Gaspari, R. Yu, J. Tami, F.A. Dorr, and K.L. Sewell, Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease, Aliment. Pharmacol. Ther., 16: 1761–1770, 2002. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• M.A. Liu, DNA vaccines: a review, J. Intern. Med., 253: 402–410, 2003. [CSA]
   PubMed Web of Science ®Google Scholar
• G.A. Prince, J.J. Mond, D.D. Porter, K.C. Yim, S.J. Lan, and D.M. Klinman, Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant, J. Virol., 77: 13156–13160, 2003. [CSA]
   PubMed Web of Science ®Google Scholar
• D.M. Klinman, D. Verthelyi, F. Takeshita, and K.J. Ishii, Immune recognition of foreign DNA: A cure for bioterrorism? Immunity, 11: 123–129, 1999. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• C. von Hunolstein, S. Mariotti, R. Teloni, G. Alfarone, G. Romagnoli, G. Orefici, and R. Nisini, The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines, Vaccine, 19: 3058–3066, 2001. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• N.J. Temperton, D.C. Quenelle, K.M. Lawson, J.N. Zuckerman, E.R. Kern, P.D. Griffiths, and V.C. Emery, Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides, J. Med. Virol., 70: 86–90, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• A. Al Mariri, A. Tibor, P. Mertens, B. De, X.P. Michel, J. Godefroid, K. Walravens, and J.J. Letesson, Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant, Infect. Immun., 69: 4816–4822, 2001. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• P.J. Hogarth, K.J. Jahans, R. Hecker, R.G. Hewinson, and M.A. Chambers, Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs, Vaccine, 21: 977–982, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Z. Su, M.F. Tam, D. Jankovic, and M.M. Stevenson, Vaccination with novel immunostimulatory adjuvants against blood-stage malaria in mice, Infect. Immun., 71: 5178–5187, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• S. Mendez, K. Tabbara, Y. Belkaid, S. Bertholet, D. Verthelyi, D. Klinman, R.A. Seder, and D.L. Sacks, Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability, Infect. Immun., 71: 5121–5129, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• F.M. Frank, P.B. Petray, S.I. Cazorla, M.C. Munoz, R.S. Corral, and E.L. Malchiodi, Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes, Vaccine, 22: 77–86, 2003. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar